My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

NeoGenomics, Inc. - Common Stock (NQ:NEO)

11.43 +1.29 (+12.72%)

Streaming Delayed Price Updated: 1:11 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

May 26, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics to Participate in Upcoming Investor Conferences

May 15, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know

May 13, 2026

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Via StockStory

Topics Economy

3 Russell 2000 Stocks We’re Skeptical Of

May 08, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

NeoGenomics Inc (NASDAQ:NEO) Crushes Estimates on Robust Clinical Growth, Launches Novel MRD Test ↗

April 28, 2026

Via Chartmill

3 Reasons NEO is Risky and 1 Stock to Buy Instead

May 06, 2026

Over the past six months, NeoGenomics’s shares (currently trading at $9.01) have posted a disappointing 13.4% loss, well below the S&P 500’s 7.1% gain. This ...

Via StockStory

Topics Bankruptcy Stocks Supply Chain

5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call

May 05, 2026

NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan...

Via StockStory

Topics Earnings

NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth

April 29, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye...

Via StockStory

NeoGenomics (NEO) Q1 2026 Earnings Transcript ↗

April 28, 2026

NeoGenomics (NEO) Q1 2026 Earnings Transcript

Via The Motley Fool

NeoGenomics (NEO) Q1 2025 Earnings Transcript ↗

April 28, 2026

NeoGenomics (NEO) Q1 2025 Earnings Transcript

Via The Motley Fool

NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue

April 28, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 11.1% yea...

Via StockStory

NeoGenomics Reports First Quarter 2026 Results

April 28, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics NEO Q2 2025 Earnings Transcript ↗

April 28, 2026

NeoGenomics NEO Q2 2025 Earnings Transcript

Via The Motley Fool

Topics Retirement

NeoGenomics Earnings: What To Look For From NEO

April 26, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. ...

Via StockStory

Why NeoGenomics (NEO) Stock Is Trading Up Today

April 24, 2026

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 4.1% in the afternoon session after the company announced that...

Via StockStory

Topics Artificial Intelligence

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

April 23, 2026

From NeoGenomics, Inc.

Via Business Wire

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

April 23, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...

Via StockStory

NeoGenomics (NEO) Q4 2024 Earnings Transcript ↗

April 22, 2026

NeoGenomics (NEO) Q4 2024 Earnings Transcript

Via The Motley Fool

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

3 Unprofitable Stocks Walking a Fine Line

April 21, 2026

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...

Via StockStory

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

April 13, 2026

From NeoGenomics, Inc.

Via Business Wire

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

April 12, 2026

Let’s dig into the relative performance of NeoGenomics (NASDAQ:NEO) and its peers as we unravel the now-completed Q4 testing & diagnostics services earnings ...

Via StockStory

3 Cash-Burning Stocks We Think Twice About

April 08, 2026

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Via StockStory

Topics Economy

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

April 07, 2026

From NeoGenomics, Inc.

Via Business Wire

3 of Wall Street’s Favorite Stocks We Think Twice About

April 02, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

March 23, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

March 16, 2026

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Via StockStory

Topics Economy Stocks

NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

March 16, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Reasons to Avoid NEO and 1 Stock to Buy Instead

February 25, 2026

What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have...

Via StockStory

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

February 25, 2026

From NeoGenomics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.